Pitocin is a prescription injectable medication containing oxytocin, used to induce or strengthen labor by stimulating uterine contractions. It is administered intravenously and manufactured by Endo USA, Inc. This information was generated using AI and is provided for informational and research purposes only.

Per-batch lab-verified Certificates of Analysis for Oxytocin: purity, endotoxin, sterility, heavy-metal results, and vendor attribution.

The size of the Oxytocin Supplement market was valued at USD 90 million in 2023 and is projected to reach USD 153.25 million by 2032, with an expected CAGR of 7.9% during the forecast period.

Oxytocin Injection Market size, share, and trend analysis indicates growth from USD 873 Million in 2025 to USD 1.64 Billion by 2035, at a CAGR of 6.5%

Analyze Oxytocin import export data with detailed shipment records, HS codes, importing countries, top buyers, suppliers, and global trade trends.

It has been demonstrated that secretion of several hormones can be classically conditioned, however, the underlying brain responses of such conditioning have never been investigated before. In this study we aimed to investigate how oxytocin administration and classically conditioned oxytocin influence brain responses. In total, 88 females were allocated to one of three groups: oxytocin administration, conditioned oxytocin, or placebo, and underwent an experiment consisting of three acquisition and three evocation days. Participants in the conditioned group received 24 IU of oxytocin together with a conditioned stimulus (CS) during three acquisition days and placebo with the CS on three evocation days. The oxytocin administration group received 24 IU of oxytocin and the placebo group received placebo during all days. On the last evocation day, fMRI scanning was performed for all participants during three tasks previously shown to be affected by oxytocin: presentation of emotional faces, crying baby sounds and heat pain. Region of interest analysis revealed that there was significantly lower activation in the right amygdala and in two clusters in the left superior temporal gyrus in the oxytocin administration group compared to the placebo group in response to observing fearful faces. The activation in the conditioned oxytocin group was in between the other two groups for these clusters but did not significantly differ from either group. No group differences were found in the other tasks. Preliminary evidence was found for brain activation of a conditioned oxytocin response; however, despite this trend in the expected direction, the conditioned group did not significantly differ from other groups. Future research should, therefore, investigate the optimal timing of conditioned endocrine responses and study whether the findings generalize to other hormones as well.

Experimental studies exploring the effects of intranasal oxytocin are typically underpowered due to small samples. Open access to experimental data and procedures and the use of previously employed measures is critical to building more robust and replicable findings, especially in less studied areas of oxytocin research. In this paper, data is provided from a double-blind placebo-controlled crossover study exploring the effects of intranasal oxytocin (IN-OT: 24 IU) on social preference to romantic partners, parents, peers, and strangers. Young adults (N=44; 91% female) in committed dating relationships completed three phases of data collection including a screening survey followed by two laboratory visits. In addition to romantic partner-, and stranger attraction ratings, the data is the first to provide comparisons between attachment and social preference ratings to parents, close friends, and romantic partners under placebo and IN-OT conditions. The data also include differences by situational and life history factors known to moderate oxytocin effects. The detailed protocol, and dataflow can be accessed to verify the analysis and findings or to conduct a replication study. The standardized experimental design and common IN-OT protocol add to the capacity for a meta-analysis exploring oxytocin effects on partner preference, and may also be directly ported to existing or future studies with related questions to increase sample size and power.

Oxytocin Market size, share, and trend analysis indicates growth from USD 1.3 Billion in 2025 to USD 2.94 Billion by 2035, at a CAGR of 8.5%

This pathway shows a high-level overview of oxytocin signalling.

Aggregate COA test results for Oxytocin: purity statistics, safety panel coverage, and lab breakdown from Disclosed's verified COA corpus.

CEP certificate for Oxytocin issued by EDQM. Includes certificate number CEP 2000-150 - Rev 05, status Valid, and country Netherlands.

The size of the Global Oxytocin Market market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 5.40% during the forecast period. Recent developments include: In August 2022, Tonix Pharmaceuticals received the United States patent for intranasal Oxytocin (TNX-1900) for pain treatment. The patent, titled "Magnesium-Containing Oxytocin Formulations and Methods of Use," claimed methods and compositions for treating pain, including that incident to migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with U.S. market exclusivity until January 2036., In May 2022, the Central government of India allowed the import of oxytocin reference standards for testing and analysis after submitting a test license issued by the Drugs Controller General of India (DCGI).. Key drivers for this market are: Increasing Prevalence of Pregnancy Complications, Rising Number of Births Globally; Growing Awareness of Induced Labor and Breastfeeding. Potential restraints include: Stringent Regulations and High Cost of Oxytocin Drug. Notable trends are: Antepartum Segment is Expected to Witness Growth Over the Forecast Period.

Structured dataset of patents, exclusivities, generic approvals, litigation, and market intelligence for oxytocin.

Clinical trials database for Coagulation Changes With Oxytocin

Anonymized, aggregated first-party data among about 683 ProtocolPlus users tracking PT-141 (bremelanotide) or oxytocin for sexual desire and intimacy. Adoption split: PT-141 62% (421 users), oxytocin 38% (262 users). About 19% (130 users) co-track both. Switching leans toward PT-141: roughly 27% of oxytocin users (71) later moved to or added PT-141, versus about 9% of PT-141 users (38) the other way (net about 33 toward PT-141). No structured side-effect comparison or per-use cost data is available for this pair. This is a usage and switching signal reflecting what the community DOES for desire; it is NOT a statement that either compound is effective, safe, or recommended. PT-141 (Vyleesi) is FDA-approved only for acquired, generalized HSDD in premenopausal women; intranasal/sublingual oxytocin for libido is off-label.

Global trade data of Oxytocin under 30049099000, 30049099000 global trade data, trade data of Oxytocin from 80+ Countries.

Images were analyzed using Fiji ImageJ software (version 2.14.0/1.54f). Images were split into four channels:

Channel 0 = DAPI Channel 1 = Drd1 Channel 2 = Drd2 Channel 3 = Oxtr

Regions of interest (ROIs) outlining DAPI-stained nuclei were automatically generated in Fiji ImageJ. Thresholds for DAPI nuclear staining were manually established to eliminate background and accurately overlay nuclei. DAPI Mask Validation

Accuracy was verified in 10% of images (one per animal) by comparing experimenter-counted vs. automatic nuclei counts. Counts differed by ≤5%, supporting the reliability of automatic ROI generation.

Signal Detection & Quantification

The DAPI mask overlay was applied to Drd1, Drd2, and Oxtr images (Fig. 1C). A white top-hat transformation enhanced contrast, improving bright feature detection. Collected signal data included:

ROI number (nucleus number) Minimum, mean, and maximum intensity values % area (for both 16-bit and 8-bit data)

Data Processing & Analysis...

PSI's curated index of 50 peer-reviewed studies on Oxytocin, prioritized by evidence strength: human clinical research first, then animal studies.

Abstract Decision-making in groups is a remarkable and decisive element of human societies. Humans are able to organize themselves in groups, engage in collaborative decision-making processes and arrive at a binding agreement, even in the absence of unanimous consent. However, the transfer of decision-making autonomy requires a willingness to deliberately expose oneself to the decisions of others. A lack of trust in the abilities of others or of the underlying decisionmaking process, i.e. public trust, can lead to a breakdown of organizations in political or economic domains. Recent studies indicate that the biological basis of trust on an individual level is related to Oxytocin, an endogenous neuropeptide and hormone, which is also associated with pro-social behavior and positive conflict resolution. However, little is known about the effects of Oxytocin on the inclination of individuals to form or join groups and to deliberately engage in collaborative decision-making processes. Here, we show that intranasal administration of Oxytocin (n = 60) compared to placebo (n = 60) in males causes an adverse effect on the choice for forming groups in the presence of a competitive environment. In particular, Oxytocin negatively affects the willingness to work collaboratively in a p-Beauty contest game, whereas the effect is most pronounced for participants with relatively high strategic sophistication. Since our data provide initial evidence that Oxytocin has a positive effect on strategic thinking and performance in the p-Beauty contest game, we argue that the adverse effect on group formation might be rooted in an enhanced strategic sophistication of participants treated with Oxytocin.

Official FDA Orange Book data for OXYTOCIN (OXYTOCIN): NDA 018248, therapeutic-equivalence code, listed patents, and marketing exclusivity.